Key result
New observational protocol evaluates CYP2C19 genotype impact on major CV events in clopidogrel-treated ischemic stroke patients.
Why the study?
Little is known about whether CYP2C19 genotype influences the preventive efficacy of clopidogrel against composite cardiovascular events in patients with stroke.
Does loss-of-function CYP2C19 genotype increase the risk of composite cardiovascular events in acute ischaemic stroke patients treated with clopidogrel compared to extensive metabolisers?
Population
Patients with acute ischaemic stroke receiving clopidogrel within 72 hours of onset and evaluated for CYP2C19 genotype
Comparison
CYP2C19 poor or intermediate metabolisers vs extensive metabolisers
Design
Prospective multicentre observational study protocol
Follow-up
6 months
Authors
Loading...
This protocol describes a prospective observational study to evaluate whether CYP2C19 genotype influences the efficacy of clopidogrel for secondary prevention in patients with acute ischemic stroke.
Observational
Yes
Does loss-of-function CYP2C19 genotype increase the risk of composite cardiovascular events in acute ischaemic stroke patients treated with clopidogrel compared to extensive metabolisers?
This protocol describes a prospective observational study to evaluate whether CYP2C19 genotype influences the efficacy of clopidogrel for secondary prevention in patients with acute ischemic stroke.
Song et al. (2020) conducted an observational in Acute ischaemic stroke. Loss-of-function CYP2C19 genotype (poor and intermediate metabolisers) vs. Extensive metabolisers (non-carriers) was evaluated on Composite cardiovascular events (stroke, myocardial infarction, or cardiovascular death). This study is a protocol for a prospective observational multicentre study to evaluate the effect of CYP2C19 genotype on cardiovascular events in patients with ischaemic stroke taking clopidogrel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: